Elevated plasma urokinase receptor predicts low birth weight in maternal malaria

Parasite Immunology

Volumn 29, Issue 1, 2007, Pages 37-46

  Ostrowski, S R ^a   Shulman, C E ^b,c   Peshu, N ^c   Staalsoe T ^a,d   Hoyer Hansen G ^e   Pedersen, B K ^a   Marsh, K ^c   Ullum, H ^a  

^a University of Copenhagen   (Denmark)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e FINSEN LABORATORY   (Denmark)

Author keywords

Birth weight; Cord blood; Immune activation; Maternal malaria; suPAR; Urokinase receptor

Indexed keywords

SOLUBLE UROKINASE RECEPTOR; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BIRTH WEIGHT; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNE SYSTEM; KENYA; LINEAR REGRESSION ANALYSIS; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALARIA; MATERNAL DISEASE; MATERNAL PLASMA; MULTIVARIATE ANALYSIS; PREDICTION; PREGNANCY; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33845582685     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2006.00916.x     Document Type: Article

References (60)

1. Malaguarnera L & Musumeci S. The immune response to Plasmodium falciparum malaria. Lancet Infect Dis 2002; 2: 472-478.
2. Miller LH, Baruch DI, Marsh K & Doumbo OK. The pathogenic basis of malaria. Nature 2002; 415: 673-679.
3. Grau GE, Taylor TE, Molyneux ME et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989; 320: 1586-1591.
4. Kwiatkowski D, Hill AV, Sambou I et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990; 336: 1201-1204.
5. Odeh M. The role of tumour necrosis factor-alpha in the pathogenesis of complicated falciparum malaria. Cytokine 2001; 14: 11-18.
6. Fried M, Muga RO, Misore AO & Duffy PE. Malaria elicits type 1 cytokines in the human placenta: IFN-gamma and TNF-alpha associated with pregnancy outcomes. J Immunol 1998; 160: 2523-2530.
7. Moormann AM, Sullivan AD, Rochford RA et al. Malaria and pregnancy: placental cytokine expression and its relationship to intrauterine growth retardation. J Infect Dis 1999; 180: 1987-1993.
8. Rogerson SJ, Brown HC, Pollina E et al. Placental tumor necrosis factor alpha but not gamma interferon is associated with placental malaria and low birth weight in Malawian women. Infect Immun 2003; 71: 267-270.
9. Perch M, Kofoed PE, Fischer TK et al. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 2004; 26: 207-211.
10. Ostrowski SR, Ullum H, Goka BQ et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005; 191: 1331-1441.
11. Sidenius N, Sier CF, Ullum H et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-4095.
12. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK & Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immun Defic Syndr 2005; 39: 23-31.
13. ter Kuile FO, Parise ME, Verhoeff FH et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2004; 71: 41-54.
14. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003; 9: 1499-1528.
15. Nykjaer A, Moller B, Todd RF et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 1994; 152: 505-516.
16. Nykjaer A, Petersen CM, Moller B, Andreasen PA & Gliemann J. Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine activated killer cells. FEBS Lett 1992; 300: 13-17.
17. Plesner T, Ralfkiaer E, Wittrup M et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994; 102: 835-841.
18. Haddock RC, Spell ML, Baker CD III et al. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem 1991; 266: 21466-21473.
19. Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A & Preissner KT. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost 1997; 77: 540-547.
20. de Bock CE & Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004; 24: 13-39.
21. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F & Dano K. Cellular receptor for urokinase plasminogen activator. Carboxylterminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 1991; 266: 1926-1933.
22. Wilhelm OG, Wilhelm S, Escott GM et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 1999; 180: 225-235.
23. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714-724.
24. Blasi F & Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
25. Mondino A & Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004; 25: 450-455.
26. Shulman CE, Marshall T, Dorman EK et al. Malaria in pregnancy: adverse effects on haemoglobin levels and birthweight in primigravidae and multigravidae. Trop Med Int Health 2001; 6: 770-778.
27. Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K & Hviid L. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 2004; 363: 283-289.
28. Bulmer JN, Rasheed FN, Francis N, Morrison L & Greenwood BM. Placental malaria. I. Pathological classification. Histopathology 1993; 22: 211-218.
29. Riisbro R, Christensen IJ, Piironen T et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002; 8: 1132-1141.
30. Riisbro R, Piironen T, Brünner N et al. Measurements of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay 2002; 25: 53-56.
31. Holst-Hansen C, Hamers MJ, Johannessen BE, Brunner N & Stephens RW. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer 1999; 81: 203-211.
32. Chavakis T, Kanse SM, Yutzy B, Lijnen HR & Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91: 2305-2312.
33. Mustjoki S, Sidenius N & Vaheri A. Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells. FEBS Lett 2000; 486: 237-242.
34. Karunaweera ND, Grau GE, Gamage P, Carter R & Mendis KN. Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci USA 1992; 89: 3200-3203.
35. Kwiatkowski D, Cannon JG, Manogue KR, Cerami A, Dinarello CA & Greenwood BM. Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol 1989; 77: 361-366.
36. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991; 285: 199-212.
37. Roebuck KA & Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999; 66: 876-888.
38. Beeson JG & Brown GV. Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation. Cell Mol Life Sci 2002; 59: 258-271.
39. Dekkers PE, ten Hove T, te Velde AA, van Deventer SJ & van Der PT. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun 2000; 68: 2156-2160.
40. Sitrin RG, Todd RF III, Mizukami IF, Gross TJ, Shollenberger SB & Gyetko MR. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 1994; 84: 1268-1275.
41. Chavakis T, Willuweit AK, Lupu F, Preissner KT & Kanse SM. Release of soluble urokinase receptor from vascular cells. Thromb Haemost 2001; 86: 686-693.
42. Juffermans NP, Dekkers PE, Verbon A, Speelman P, van Deventer SJ & van Der PT. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun 2001; 69: 5182-5185.
43. Coleman JL, Gebbia JA & Benach JL. Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87). J Immunol 2001; 166: 473-480.
44. Brabin BJ, Romagosa C, Abdelgalil S et al. The sick placenta - the role of malaria. Placenta 2004; 25: 359-378.
45. Steketee RW, Nahlen BL, Parise ME & Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64: 28-35.
46. van Geertruyden JP, Thomas F, Erhart A & D'Alessandro U. The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg 2004; 71: 35-40.
47. Solberg H, Ploug M, Hoyer-Hansen G, Nielsen BS & Lund LR. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 2001; 49: 237-246.
48. Wegmann TG, Lin H, Guilbert L & Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14: 353-356.
49. WHO Expert Committee on Malaria. WHO Technical Report Series-892. Twentieth Report. Geneva: World Health Organization; 2000.
50. Shulman CE, Dorman EK, Talisuna AO et al. A community randomized controlled trial of insecticide-treated bednets for the prevention of malaria and anaemia among primigravid women on the Kenyan coast. Trop Med Int Health 1998; 3: 197-204.
51. Pouvelle B, Buffet PA, Lepolard C, Scherf A & Gysin J. Cytoadhesion of Plasmodium falciparum ring-stage-infected erythrocytes. Nat Med 2000; 6: 1264-1268.
52. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK & Ullum H. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immun Defic Syndr 2004; 35: 337-342.
53. Cinque P, Nebuloni M, Santovito ML et al. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol 2004; 55: 687-694.
54. Jaffar S, Van der Loeff MS, Eugen-Olsen J et al. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau. AIDS Res Hum Retroviruses 2005; 21: 560-564.
55. Eugen-Olsen J, Gustafson P, Sidenius N et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002; 6: 686-692.
56. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG & Todd RF. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995; 86: 203-211.
57. Florquin S, van den Berg JG, Olszyna DP et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001; 59: 2054-2061.
58. Wittenhagen P, Kronborg G, Weis N et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004; 10: 409-415.
59. Garcia-Monco JC, Coleman JL & Benach JL. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol 2002; 129: 216-223.
60. Riisbro R, Christensen IJ, Hogdall C, Brunner N & Hogdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001; 16: 233-239.